|
|
 |
|
Total Number of Holdings (excluding cash): 50
| Eli Lilly and Company |
LLY |
532457108 |
Pharmaceuticals |
2,475 |
$2,788,830.00 |
7.93% |
| Merck & Co., Inc. |
MRK |
58933Y105 |
Pharmaceuticals |
21,021 |
$2,520,207.69 |
7.16% |
| AbbVie Inc. |
ABBV |
00287Y109 |
Pharmaceuticals |
11,216 |
$2,452,154.08 |
6.97% |
| Johnson & Johnson |
JNJ |
478160104 |
Pharmaceuticals |
10,477 |
$2,418,091.60 |
6.87% |
| Bristol-Myers Squibb Company |
BMY |
110122108 |
Pharmaceuticals |
41,733 |
$2,375,025.03 |
6.75% |
| Viatris Inc. |
VTRS |
92556V106 |
Pharmaceuticals |
87,169 |
$1,404,292.59 |
3.99% |
| Biogen Inc. |
BIIB |
09062X103 |
Biotechnology |
6,784 |
$1,332,309.76 |
3.79% |
| Pfizer Inc. |
PFE |
717081103 |
Pharmaceuticals |
47,068 |
$1,230,357.52 |
3.50% |
| Gilead Sciences, Inc. |
GILD |
375558103 |
Pharmaceuticals |
8,738 |
$1,190,290.36 |
3.38% |
| Vertex Pharmaceuticals Incorporated |
VRTX |
92532F100 |
Pharmaceuticals |
2,620 |
$1,173,681.40 |
3.34% |
| Cardinal Health, Inc. |
CAH |
14149Y108 |
Pharmaceuticals |
5,678 |
$1,134,748.30 |
3.23% |
| Amgen Inc. |
AMGN |
031162100 |
Pharmaceuticals |
3,353 |
$1,128,217.44 |
3.21% |
| United Therapeutics Corporation |
UTHR |
91307C102 |
Pharmaceuticals |
1,920 |
$1,079,212.80 |
3.07% |
| Regeneron Pharmaceuticals, Inc. |
REGN |
75886F107 |
Biotechnology |
1,665 |
$1,034,830.80 |
2.94% |
| Jazz Pharmaceuticals Plc |
JAZZ |
G50871105 |
Pharmaceuticals |
3,943 |
$928,103.34 |
2.64% |
| Incyte Corporation |
INCY |
45337C102 |
Biotechnology |
8,062 |
$786,045.00 |
2.23% |
| Zoetis Inc. |
ZTS |
98978V103 |
Pharmaceuticals |
9,927 |
$776,986.29 |
2.21% |
| Illumina, Inc. |
ILMN |
452327109 |
Biotechnology |
4,308 |
$683,679.60 |
1.94% |
| Exelixis, Inc. |
EXEL |
30161Q104 |
Biotechnology |
12,111 |
$623,110.95 |
1.77% |
| Neurocrine Biosciences, Inc. |
NBIX |
64125C109 |
Biotechnology |
3,099 |
$484,652.61 |
1.38% |
| Medpace Holdings, Inc. |
MEDP |
58506Q109 |
Biotechnology |
1,019 |
$456,634.28 |
1.30% |
| PTC Therapeutics, Inc. |
PTCT |
69366J200 |
Biotechnology |
6,420 |
$456,141.00 |
1.30% |
| Charles River Laboratories International, Inc. |
CRL |
159864107 |
Biotechnology |
2,505 |
$454,256.70 |
1.29% |
| Halozyme Therapeutics, Inc. |
HALO |
40637H109 |
Biotechnology |
5,896 |
$401,989.28 |
1.14% |
| Alkermes Plc |
ALKS |
G01767105 |
Pharmaceuticals |
9,873 |
$394,327.62 |
1.12% |
| BioMarin Pharmaceutical Inc. |
BMRN |
09061G101 |
Pharmaceuticals |
7,443 |
$392,543.82 |
1.12% |
| Elanco Animal Health Incorporated |
ELAN |
28414H103 |
Pharmaceuticals |
12,871 |
$308,646.58 |
0.88% |
| Spyre Therapeutics, Inc. |
SYRE |
00773J202 |
Biotechnology |
4,162 |
$300,121.82 |
0.85% |
| Travere Therapeutics, Inc. |
TVTX |
89422G107 |
Pharmaceuticals |
6,008 |
$286,942.08 |
0.82% |
| Twist Bioscience Corporation |
TWST |
90184D100 |
Biotechnology |
3,815 |
$263,349.45 |
0.75% |
| Guardant Health, Inc. |
GH |
40131M109 |
Biotechnology |
1,906 |
$253,917.32 |
0.72% |
| Arrowhead Pharmaceuticals, Inc. |
ARWR |
04280A100 |
Biotechnology |
3,076 |
$243,157.80 |
0.69% |
| Catalyst Pharmaceuticals, Inc. |
CPRX |
14888U101 |
Biotechnology |
7,756 |
$242,685.24 |
0.69% |
| TG Therapeutics, Inc. |
TGTX |
88322Q108 |
Biotechnology |
5,948 |
$230,901.36 |
0.66% |
| 10X Genomics, Inc. (Class A) |
TXG |
88025U109 |
Biotechnology |
7,765 |
$217,342.35 |
0.62% |
| Arcus Biosciences, Inc. |
RCUS |
03969F109 |
Biotechnology |
8,787 |
$215,105.76 |
0.61% |
| Ligand Pharmaceuticals Inc. (Class B) |
LGND |
53220K504 |
Biotechnology |
902 |
$211,663.32 |
0.60% |
| Krystal Biotech, Inc. |
KRYS |
501147102 |
Biotechnology |
649 |
$201,384.70 |
0.57% |
| Amneal Pharmaceuticals, Inc. |
AMRX |
03168L105 |
Pharmaceuticals |
15,297 |
$198,096.15 |
0.56% |
| Mirum Pharmaceuticals, Inc. |
MIRM |
604749101 |
Biotechnology |
1,940 |
$193,224.00 |
0.55% |
| Protagonist Therapeutics, Inc. |
PTGX |
74366E102 |
Biotechnology |
1,944 |
$195,197.04 |
0.55% |
| Roivant Sciences Ltd. |
ROIV |
G76279101 |
Biotechnology |
6,185 |
$184,807.80 |
0.53% |
| Ionis Pharmaceuticals, Inc. |
IONS |
462222100 |
Pharmaceuticals |
2,205 |
$170,512.65 |
0.48% |
| Alnylam Pharmaceuticals, Inc. |
ALNY |
02043Q107 |
Biotechnology |
538 |
$164,122.28 |
0.47% |
| ACADIA Pharmaceuticals Inc. |
ACAD |
004225108 |
Biotechnology |
7,288 |
$157,639.44 |
0.45% |
| Kymera Therapeutics, Inc. |
KYMR |
501575104 |
Biotechnology |
1,960 |
$159,661.60 |
0.45% |
| Moderna, Inc. |
MRNA |
60770K107 |
Biotechnology |
3,341 |
$158,931.37 |
0.45% |
| Supernus Pharmaceuticals, Inc. |
SUPN |
868459108 |
Pharmaceuticals |
3,271 |
$153,246.35 |
0.44% |
| Arcutis Biotherapeutics, Inc. |
ARQT |
03969K108 |
Biotechnology |
6,637 |
$142,297.28 |
0.40% |
| Tarsus Pharmaceuticals, Inc. |
TARS |
87650L103 |
Biotechnology |
2,371 |
$141,169.34 |
0.40% |
| US Dollar |
$USD |
|
Other |
88,240 |
$88,240.06 |
0.25% |
Holdings are subject to change.
The holdings information set forth above for the date indicated reflects creation and redemption transactions from the prior business day and may differ from the holdings information currently available from the Fund's custodian and accounting agent. With respect to the market value of the Fund's holdings set forth above, the pricing sources are generally third party vendors. The Fund ultimately relies on pricing information provided by the Fund's accounting agent.
|
|
The information presented is not intended to constitute an investment recommendation for, or advice to, any specific person. By providing this information, First Trust is not undertaking to give advice in any fiduciary capacity within the meaning of ERISA, the Internal Revenue Code or any other regulatory framework. Financial professionals are responsible for evaluating investment risks independently and for exercising independent judgment in determining whether investments are appropriate for their clients.
|